-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Spinal Muscular Atrophy (SMA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Spinal Muscular Atrophy (SMA) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apitegromab in Spinal Muscular Atrophy (SMA)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Apitegromab in Spinal Muscular Atrophy (SMA) Drug Details: Apitegromab (SRK-015) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vartocell in Spinal Muscular Atrophy (SMA)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Vartocell in Spinal Muscular Atrophy (SMA)Drug Details:Vartocell is under development for the treatment of acute myocardial...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NMDP-02 in Spinal Muscular Atrophy (SMA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NMDP-02 in Spinal Muscular Atrophy (SMA) Drug Details: NMDP-02 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIIB-115 in Spinal Muscular Atrophy (SMA)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-115 in Spinal Muscular Atrophy (SMA) Drug Details: BIIB-115 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Talditercept Alfa in Spinal Muscular Atrophy (SMA)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talditercept Alfa in Spinal Muscular Atrophy (SMA) Drug Details: Talditercept alfa (RG-6206) is under...
-
Sector Analysis
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Report Overview Spinal muscular atrophy (SMA) is a group of clinically and genetically heterogenous inherited neuromuscular disorders characterized by the loss of lower motor neurons in the spinal cord, resulting in progressive muscle weakness, muscle wasting, and low muscle tone. However, neurons controlling most voluntary muscles like those involved in feeding, swallowing, and breathing can also be affected. Key Mechanism of Action (Marketed) ·      Protein or Peptide Activator ·      Receptor Agonist Key...
-
SMA Projects/ Veriu Hotels – Punthill Sunshine Apartment Hotel Development – Victoria
Equip yourself with the essential tools needed to make informed and profitable decisions with our SMA Projects/ Veriu Hotels – Punthill Sunshine Apartment Hotel Development – Victoria report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:Dive...
-
Product Insights
SMA Projects/ VicTrack – 24 Chapel Street Residential Tower – Victoria
Equip yourself with the essential tools needed to make informed and profitable decisions with our SMA Projects/ VicTrack - 24 Chapel Street Residential Tower - Victoria report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
SMA Equities – Gramercy Park Submarket Mixed-Use Residential Complex – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our SMA Equities - Gramercy Park Submarket Mixed-Use Residential Complex - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
New![]()
Net Present Value Model: Scholar Rock Holding Corp’s Apitegromab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Scholar Rock Holding Corp's Apitegromab Drug Details: Apitegromab (SRK-015) is under development for the treatment of type 2 and type 3 spinal muscular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Pancreatic Ductal Adenocarcinoma Drug Details: SLATE-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Colorectal Cancer Drug Details: SLATE-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Solid Tumor Drug Details: SLATE-001 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)Drug Details: Amifampridine phosphate is under development for the...
-
Company Profile
![]()
SMA Solar Technology AG – Company Profile
SMA Solar Technology AG (SMA) is a renewable energy company. It develops, produces, and distributes photovoltaic inverters, choke coils, transformers, and monitoring and energy management systems for PV systems. It also offers intelligent energy management system and digital services, as well as solar power plant operation and maintenance. It serves customers in South America, Asia Pacific, North America, Europe, the Middle East, and Africa. Its R&D efforts focus on developing complete system solutions and digital business models. The company has...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CBP-1019 in Colorectal CancerDrug Details: CBP-1019 is under development for the treatment of lung cancer, colorectal...
-
Track & Monitor
New![]()
Innovation in technology: Photovoltaic cell testing
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the technology industry’s Photovoltaic cell testing innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Bupropion Hydrochloride + Naltrexone) Er in Smoking Cessation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Bupropion Hydrochloride + Naltrexone) Er in Smoking CessationDrug Details:Bupropion hydrochloride and Naltrexone (Contrave, Mysimba) is a...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.